Biomarker exposure-response relationships as the basis for rational dose selection: Lessons from a simulation exercise using a selective COX-2 inhibitor

Journal of Clinical Pharmacology
A TanejaO Della Pasqua

Abstract

An exposure-response model was used to characterize the pharmacokinetic-pharmacodynamic relationship of GW406381, a COX-2 inhibitor, based on data from ex vivo prostaglandin E2 inhibition collected in a phase 1 study in healthy subjects. The final model was then used to simulate a proof-of-concept study and to explore suitable dosing ranges in case of hepatic dysfunction or metabolic induction. Trough concentrations in the range of IC80 to IC95 were used as target therapeutic concentrations. Symptom relief in a subsequent phase 2b study in 400 patients with rheumatoid arthritis receiving GW406381 was then analysed to support the design of a phase 3 study in which doses in the range between 10 to 400 mg were explored. The exercise also allowed the evaluation of correlations between the biomarker and clinical end point. A 2-compartment model described the pharmacokinetics of GW406381, whereas the pharmacodynamics was described by an Imax model. In patients with normal organ function, the predicted median therapeutic dose was between 100 and 150 mg. The time course of symptom relief was fitted by a Weibull model, with an Imax model describing the drug effect. Simulations showed that dose-response discrimination occurred at doses h...Continue Reading

References

Jul 29, 1998·Journal of Pharmacokinetics and Biopharmaceutics·K ParkL B Sheiner
Jul 24, 2001·Anesthesiology·C J Woolf, M B Max
Nov 13, 2002·Pharmacoepidemiology and Drug Safety·Eibert R HeerdinkHubert G Leufkens
Aug 3, 2004·Nature Reviews. Drug Discovery·Ismail Kola, John Landis
Sep 28, 2004·Basic & Clinical Pharmacology & Toxicology·Camilla Staahl, Asbjørn Mohr Drewes
Mar 8, 2005·Trends in Pharmacological Sciences·Raymond A DionneJames Witter
Oct 15, 2005·Nature Reviews. Drug Discovery·Fletcher A WhiteRichard J Miller
Jan 6, 2006·The Journal of Clinical Investigation·Tilo GrosserGarret A FitzGerald
Jan 13, 2006·Gastroenterology·Susanne FriesGarret A FitzGerald
May 10, 2006·British Journal of Pharmacology·Dymphy R H HuntjensOscar E Della Pasqua
Apr 5, 2008·Current Opinion in Rheumatology·Josef S Smolen, Daniel Aletaha
Jul 9, 2008·Trends in Pharmacological Sciences·Burkhard Hinz, Kay Brune
Sep 9, 2008·European Journal of Pain : EJP·Dymphy R H HuntjensOscar E Della Pasqua
Jan 27, 2009·Brain Research Reviews·Boris A ChizhKlaus Schaffler
Feb 24, 2009·Toxicologic Pathology·Zaher A Radi
Sep 11, 2009·British Journal of Clinical Pharmacology·Camilla StaahlAsbjørn Mohr Drewes
Feb 20, 2010·Current Medicinal Chemistry·Asit K ChakrabortiPradeep S Jadhavar
Jul 14, 2010·Journal of Clinical Pharmacology·Chuanpu HuHonghui Zhou
Sep 18, 2010·Nature Reviews. Drug Discovery·Adam F Cohen
Nov 3, 2011·Pharmacogenetics and Genomics·Thierry DervieuxHenk-Jan Guchelaar
Mar 12, 2013·Expert Review of Clinical Pharmacology·Karen Rowland YeoAmin Rostami-Hodjegan
Sep 23, 2014·Geriatrics & Gerontology International·Aleksandra WardzyńskaMarek Leszek Kowalski
Oct 9, 2014·Annual Review of Pharmacology and Toxicology·A F CohenG J Groeneveld
Apr 18, 2015·British Journal of Pharmacology·Tarjinder SahotaOscar Della Pasqua

❮ Previous
Next ❯

Citations

May 17, 2017·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Sebastiaan C GouloozeJ G Coen van Hasselt
Mar 29, 2019·Neurology·Daniel G GlazeUNKNOWN Rett 002 Study Group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.